Population genomic analysis is a powerful tool to understand the evolutionary history of pathogens and the factors contributing to the success or failure of lineages. These studies have significant implications for human health, as evident from our ongoing tracking of SARS-CoV-2. In their article, Gill et al. (J. L. Gill, J. Hedge, D. J. Wilson, and R. C. MacLean, mBio 12:e02168-21, 2021, https://doi.org/10.1128/mBio.02168-21) demonstrate the utility of pathogen genomic data by comprehensively elucidating the origin of methicillin-resistant Staphylococcus aureus ST239. To accomplish this, they leveraged newly developed tools for querying large genomic data sets. Overall, these analyses rely on the availability of representative genomic data along with their associated metadata-information about where and when samples were collected, clinical and epidemiological characteristics, and phenotypic properties. However, in many instances, these data are missing. Here, I borrow the term "meaningful use" from the Health IT field to describe the need to maximize the utility of genomic data and make suggestions for how to address the current limitations.
Keywords: MRSA; Staphylococcus aureus; bioinformatics; genomic databases; genomic epidemiology; population genomics.